Home » Newsletters » BioWorld Science

BioWorld Science

March 7, 2016

View Archived Issues

BioPharmX initiates phase IIa study of BPX-01 for acne

First patient dosed in phase I trial of BAX-826 for the treatment of hemophilia A

Akinion ceases further development of AKN-028 due to safety concerns

EMA grants eligibility for submission of XBiotech's MAA for Xilonix

APO-010 screening protocol approved by ethics committee

Lessons learned from nonrandomized trial of favipiravir in patients with Ebola virus disease

Novartis initiates phase I trial of LXS-196 for metastatic uveal melanoma

Novel mutations in TNNT1 gene described as cause of myopathies

UCLA sells Xtandi royalty rights to Royalty Pharma

Bristol-Myers Squibb patent describes S1P1 receptor agonists

University of Washington patents methionyl-tRNA synthetase inhibitors

PTC Therapeutics divulges anti-infective agents

FDA approves Imbruvica for first-line treatment of CLL

FDA approves Idelvion for hemophilia B

Antibe Therapeutics cleared to begin phase II study of ATB-346

PeptiDream and Lilly in technology license agreement

U.S. fast track designation granted to MEDI-8852 for patients with type A strain influenza

Merck & Co. and Mectizan Donation Program donate to END fund

Total levels of IgE are elevated in patients with hidradenitis suppurativa

Oxford BioMedica and Immune Design in expanded collaboration and license agreement

LEADER trial demonstrates cardiovascular benefit of Victoza

3SBio obtains IND clearance in China for PEG-irinotecan

Plexxikon initiates phase I study of PLX-73086

EMA launches new PRIME program

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.